OR WAIT null SECS
January 15, 2024
This paper explores the relationship between investing in pharmaceutical manufacturing risk reduction and meeting business objectives.
Recent research and perspectives shed light on an opportunity to better connect risk and knowledge through improved integration of systems.
January 10, 2024
MHRA has granted a Clinical Trial Authorization to PharmaKure for its oral combined drug for the treatment of mild cognitive impairment.
January 09, 2024
The potential for superpotent drug initiated the voluntary recall.
January 03, 2024
Revolutionary therapies restructure pharmaceutical manufacturing.
European bio/pharma companies have no choice but to invest and adapt to the evolving industry needs.
A thoughtfully constructed QRM Master Plan translates the strategy and enables a risk-based approach.
UK scientists are once again able to participate in the Horizon European research programme thanks to a deal struck in 2023.
January 02, 2024
Analytical methods and tools play a pivotal role in cleaning validation.
The EHDS aims to increase access to health data, but how will it impact pharma?